+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.

Age: 18Years - 74YearsAll GendersPhase 3
53 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of osavampator compared to a placebo as an additional treatment to delay the return of depressive symptoms in adults with major depressive disorder MDD. This Phase 3 study focuses on maintaining treatment effects in participants diagnosed with recurrent moderate or severe MDD or persistent depressive disorder who have not responded adequately to oral antidepressants. The study aims to understand whether osavampator can help prevent relapse in this population. Participants will first receive osavampator during an initial open-label treatment phase. Following this, they will be randomly assigned to receive either osavampator or a matching placebo during a double-blind maintenance period. Both treatments are given as oral tablets, and participants will continue their existing oral antidepressants at the same dose and frequency throughout the study. The study may last up to approximately 32 months from randomization. During the study, participants will be regularly monitored for relapse of depressive symptoms using the Hamilton Depression Rating Scale. Researchers will track the time from randomization to relapse or the end of the study to assess treatment maintenance. Safety and adherence will be evaluated throughout, with participants expected to comply with study procedures and restrictions. The total duration of participation varies but can extend up to nearly three years.

Age: 18Years +All GendersPhase 3
61 locations
C

Actively Recruiting

Researchers are conducting a randomized, open-label phase 3 clinical trial to compare treatments for adults with advanced or metastatic non-small cell lung cancer NSCLC who have developed resistance to immune checkpoint inhibitor therapy. The study focuses on two groups one receiving N-803 plus tislelizumab and docetaxel, and the other having previously failed immune checkpoint inhibitor therapy combined with docetaxel. The trial aims to evaluate the effectiveness and safety of these treatments compared to docetaxel alone. Participants are assigned to two cohorts and randomized in a 21 ratio to either the experimental treatment or control arm. Cohort A receives N-803, tislelizumab, and docetaxel during the first two 3-week cycles, followed by N-803 and tislelizumab until the study ends. Cohort B receives N-803, their prior failed checkpoint inhibitor, and docetaxel in the first two cycles, then N-803 and the prior checkpoint inhibitor thereafter. Control arms for both cohorts receive docetaxel monotherapy in repeated 3-week cycles. During the study, participants undergo treatment cycles every three weeks with scheduled administration of drugs via subcutaneous injection or intravenous infusion. Researchers will assess overall survival approximately 12 months after treatment begins. Participants must attend study visits and follow-ups as required. Safety and treatment effects will be monitored throughout the trial, which is expected to continue until January 2029.

Age: 18Years - 90YearsAll GendersPhase 3
49 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
P

Actively Recruiting

Researchers are evaluating the effect of dalcetrapib on cardiovascular risk in people recently hospitalized for acute coronary syndrome ACS who have a specific genetic profile AA genotype. This phase 3, randomized, double-blind, placebo-controlled study focuses on adults aged 45 years and older, aiming to assess the time to first occurrence of fatal or non-fatal myocardial infarction over an average of 30 months from randomization. The study will continue until around 200 participants experience a primary event, or until stopped at an interim analysis. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily, two 300 mg tablets or matching placebo tablets once daily. Screening includes genetic testing for the AA genotype using a specialized Genotype Assay Test. Enrollment can begin during hospitalization or after discharge, but randomization must occur within 12 weeks of the ACS event. After randomization, follow-up visits will be virtual when possible or in clinic every three months until the study ends. Assessments will continue every three months for participants who stop the study medication early. Participants will undergo medical history review and genetic testing before enrollment. During the study, researchers will monitor cardiovascular events such as heart attacks and strokes through regular assessments every three months. Safety evaluations and collection of study endpoints will continue for the duration of participation, which may last approximately 30 months or until the study stops. This includes ongoing monitoring for adverse effects and overall health status.

Age: 45Years +All GendersPhase 3
231 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.

Age: 18Years +All GendersPhase 3
120 locations
E

Actively Recruiting

Researchers are evaluating COMP360, a lab-made version of the naturally occurring compound psilocybin, to see if it can reduce symptoms of post-traumatic stress disorder PTSD. This study is a phase 2b3 clinical trial involving participants diagnosed with PTSD at least six months prior. The trial is randomized, double-blind, and includes an open-label extension to investigate the safety, tolerability, and effectiveness of different doses. Participants receive COMP360 psilocybin at varying doses of 1 mg, 10 mg, or 25 mg, administered alongside monitoring and support from a trained study team. The study compares the effects of these doses using a parallel design, with the primary focus on how symptoms change by week 8 after treatment. The intervention is combined with support throughout the study to observe participant responses. During the trial, participants will undergo assessments to measure PTSD symptom severity using the CAPS-5 scale from baseline through week 8. The study includes regular monitoring and evaluation of safety and tolerability. Participation involves multiple visits over the study period, with close observation by the research team to track symptom changes and any side effects. The entire study is expected to complete by September 2029.

Age: 18Years +All GendersPhase 2Phase 3
10 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of recombinant human plasma gelsolin rhu-pGSN combined with standard care in adults with moderate-to-severe Acute Respiratory Distress Syndrome ARDS caused by pneumonia or other infections. This Phase 2, randomized, double-blind, placebo-controlled study aims to enroll patients hospitalized within 24 hours of ARDS diagnosis, focusing on those with a low oxygenation ratio PF ratio 4150 requiring mechanical or noninvasive ventilation or high-flow oxygen support. Participants are randomly assigned to receive either rhu-pGSN or a matching saline placebo alongside standard care. The treatment involves a single loading dose of rhu-pGSN at 24 mgkg, followed by five daily doses of 12 mgkg administered intravenously through a filtered syringe. Patients receive the study drug within 48 hours of ARDS diagnosis. The study includes assessments such as blood tests, imaging, cultures, and antibody measurements at baseline and specified times. Safety reviews are conducted periodically by an independent monitoring board. Throughout the study, participants undergo detailed evaluations including medical history, infection site identification, physical exams, chest imaging, blood and sputum cultures, and laboratory tests for inflammatory markers. Follow-up occurs on Days 7, 14, 28, and 60 to assess mortality and respiratory support outcomes. Safety monitoring includes serious adverse event reviews. The total participation duration extends through at least 60 days following treatment to evaluate all-cause mortality and other clinical outcomes.

Age: 18Years +All GendersPhase 2
65 locations

1-10 of 14

1